Compare Citius Pharmaceuticals Inc (CTXR) vs Dolby Laboratories, Inc. (DLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Dolby Laboratories, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Dolby Laboratories, Inc. trades at $60.91 (market cap $5.82B). The key difference: Dolby Laboratories, Inc. is far larger — about 310.7× Citius Pharmaceuticals Inc's market cap, and Dolby Laboratories, Inc. pays a 2.32% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | DLB | |
|---|---|---|
Market Cap | $18.73M | $5.82B |
Sector | Health | Industrials |
52-Week High | $1.82 | $75.62 |
52-Week Low | $0.48 | $48.51 |
Enterprise Value | $14.95M | $5.19B |
Dividend Yield | — | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Dolby Laboratories (DLB) trades at $61.77, up 1.4% today, with a bullish technical trend and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, including Q2 2026 EPS of $0.69 versus $0.67 expected. Revenue remains stable around $1.3 billion annually, with robust gross margins of 87.61%. Recent news highlights growth in Dolby Atmos and automotive licensing, though near-term revenue volatility persists.
DLB offers a compelling valuation with a P/E of 26.29 below the analyst target of $87.50, implying significant upside. Key risks include licensing deal timing and competitive pressures in audio-video tech. Institutional sentiment is positive, with 47% of analysts rating it a Buy, but investors should monitor execution on Q4 growth guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →
